DBVT earnings: next report 2026-10-27, real EPS beat/miss history, analyst consensus Buy, P/E -3.53. Updated 2026-07-23.
DBV Technologies (DBVT) Research Hub
DBV Technologies (DBVT) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.85 USD (-11.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.53, market cap 0.33B. This hub links to the full technical, earnings and options research available for DBVT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 11.85 USD (-11.83%) |
| 52-week range | 11.815 USD – 18.5 USD |
| Trend regime | Range |
| 14-day RSI | 36.6 (Bearish) |
| Trailing P/E | -3.53 |
| Market cap | 0.33B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-27 |
Available research for DBVT
Covered Call on DBVT: how it works, illustrative setup around the real 11.85 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DBVT: how it works, illustrative setup around the real 11.85 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DBVT: how it works, illustrative setup around the real 11.85 USD price, max profit/loss, breakeven and when to use it. Educational.
DBVT technical analysis: range, last 11.85 USD, RSI 36.6, 52w range 11.815 USD–18.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DBVT in?
DBV Technologies (DBVT) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.
Is DBVT in an uptrend or downtrend?
As of 2026-09-11, DBVT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DBVT's trailing P/E ratio?
DBVT's trailing P/E is -3.53, with a market cap of 0.33B. See the earnings research page for full valuation detail.
When does DBVT next report earnings?
DBVT is next scheduled to report earnings on 2026-10-27, with a consensus EPS estimate of -0.15958 USD.